National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

< Back to Main

Related Pages
Multiple Myeloma/Other Plasma Cell Neoplasms 1
NCI's gateway for information about multiple myeloma and other plasma cell neoplasms.

Search for Clinical Trials 2
NCI's PDQ® Cancer Clinical Trials Registry.
Multiple Myeloma Trial Results
1.  Thalidomide a Beneficial Option for Elderly Multiple Myeloma Patients 3
(Posted: 02/12/2008, Updated: 06/01/2009) - Patients aged 75 and over with newly diagnosed multiple myeloma who received the drug thalidomide in addition to standard therapy (melphalan and prednisone) survived longer than patients who received standard therapy plus a placebo, according to clinical trial results presented at the 2007 annual meeting of the American Society of Hematology.

2.  Double Transplantation of One's Own Stem Cells Is Not Warranted for Multiple Myeloma 4
(Posted: 02/24/2009) - The addition of a second hematopoietic stem cell transplant procedure using one's own blood cells does not appear warranted in multiple myeloma, according to the Jan. 21, 2009, Journal of the National Cancer Institute.

3.  Thalidomide Effective in Multiple Myeloma 5
(Posted: 03/15/2006, Updated: 09/16/2008) - In the March 9, 2006, issue of the New England Journal of Medicine, researchers report superior event-free and complete response rates when the drug thalidomide was used before and during primary therapy for multiple myeloma. Longer follow-up showed a survival benefit for some patients, as well.

4.  Bortezomib Approved for First-Line Treatment of Multiple Myeloma 6
(Posted: 09/11/2008) - The targeted drug bortezomib, when added to standard therapy (melphalan and prednisone), significantly improves time to progression and overall survival in patients with newly diagnosed multiple myeloma, according to the August 28, 2008, New England journal of Medicine.

5.  Drug Combination Shows Benefit in Relapsed/Refractory Multiple Myeloma 7
(Posted: 08/28/2007) - A new combination treatment should be another standard of care for patients with relapsed or refractory multiple myeloma, according to the Sept. 1, 2007, Journal of Clinical Oncology.
1 2 8 3 9 4 10   Next > 8


Table of Links

1http://www.cancer.gov/cancertopics/types/myeloma
2http://www.cancer.gov/clinicaltrials/search
3http://www.cancer.gov/clinicaltrials/results/thalidomide0208
4http://www.cancer.gov/clinicaltrials/results/tandem-transplant0209
5http://www.cancer.gov/clinicaltrials/results/thalidomide-and-myeloma0306
6http://www.cancer.gov/clinicaltrials/results/bortezomib0908
7http://www.cancer.gov/clinicaltrials/results/myeloma0807
8http://www.cancer.gov/clinicaltrials/results/multiple-myeloma?keyword=any+myelo
ma&page=2
9http://www.cancer.gov/clinicaltrials/results/multiple-myeloma?keyword=any+myelo
ma&page=3
10http://www.cancer.gov/clinicaltrials/results/multiple-myeloma?keyword=any+myelo
ma&page=4